BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29198894)

  • 21. Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
    Barrett I; Meegan MJ; Hughes RB; Carr M; Knox AJ; Artemenko N; Golfis G; Zisterer DM; Lloyd DG
    Bioorg Med Chem; 2008 Nov; 16(21):9554-73. PubMed ID: 18835176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of novel 2-methoxyestradiol analogs as dual selective estrogen receptor modulators (SERMs) and antiangiogenic agents.
    Lao K; Wang Y; Chen M; Zhang J; You Q; Xiang H
    Eur J Med Chem; 2017 Oct; 139():390-400. PubMed ID: 28810190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of novel indole-pyrimidine hybrids bearing morpholine and thiomorpholine moieties.
    Diao PC; Li Q; Hu MJ; Ma YF; You WW; Hong KH; Zhao PL
    Eur J Med Chem; 2017 Jul; 134():110-118. PubMed ID: 28410492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
    Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
    J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A precisely substituted benzopyran targets androgen refractory prostate cancer cells through selective modulation of estrogen receptors.
    Kumar R; Verma V; Sharma V; Jain A; Singh V; Sarswat A; Maikhuri JP; Sharma VL; Gupta G
    Toxicol Appl Pharmacol; 2015 Mar; 283(3):187-97. PubMed ID: 25655200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
    Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
    Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogenic activity of bis(4-hydroxyphenyl)methanes with cyclic hydrophobic structure.
    Kojima T; Ogawa T; Kitao S; Sato M; Oda A; Ohta K; Endo Y
    Bioorg Med Chem; 2015 Nov; 23(21):6900-11. PubMed ID: 26462053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity.
    Ragab MA; Elagawany M; Daabees H; Ahmed AF; Awad EM; Billon C; Elgendy B; Abouzid KAM; Kassab SE
    Bioorg Chem; 2022 Feb; 119():105554. PubMed ID: 34923243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and Synthesis of Novel Breast Cancer Therapeutic Drug Candidates Based upon the Hydrophobic Feedback Approach of Antiestrogens.
    Ohta K; Kaise A; Taguchi F; Aoto S; Ogawa T; Endo Y
    Molecules; 2019 Nov; 24(21):. PubMed ID: 31683895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.
    Kelly PM; Bright SA; Fayne D; Pollock JK; Zisterer DM; Williams DC; Meegan MJ
    Bioorg Med Chem; 2016 Sep; 24(18):4075-4099. PubMed ID: 27407030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
    Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
    Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3',4',5'-trimethoxyphenyl)-3-(2'-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach.
    Preti D; Romagnoli R; Rondanin R; Cacciari B; Hamel E; Balzarini J; Liekens S; Schols D; Estévez-Sarmiento F; Quintana J; Estévez F
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1225-1238. PubMed ID: 30141353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
    Li X; Wu C; Lin X; Cai X; Liu L; Luo G; You Q; Xiang H
    Eur J Med Chem; 2019 Jan; 161():445-455. PubMed ID: 30384047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of certain benzyl/phenethyl thiazolidinone-indole hybrids as potential anti-proliferative agents: Synthesis, molecular modeling and tubulin polymerization inhibition study.
    Sigalapalli DK; Pooladanda V; Singh P; Kadagathur M; Guggilapu SD; Uppu JL; Tangellamudi ND; Gangireddy PK; Godugu C; Bathini NB
    Bioorg Chem; 2019 Nov; 92():103188. PubMed ID: 31450167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of carnosol against proliferative activity of breast cancer cells and its estrogen receptor subtype's mediation and regulation mechanisms].
    Zhao PW; Lee DY; Ma ZZ; Sun YL; Tao SY; Zang JF; Niu JZ
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3344-8. PubMed ID: 25522625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
    Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
    Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants.
    Kurtanović N; Tomašević N; Matić S; Mitrović MM; Kostić DA; Sabatino M; Antonini L; Ragno R; Mladenović M
    Eur J Med Chem; 2022 Jan; 227():113869. PubMed ID: 34710747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of novel indole derivatives as promising DNA-binding agents and evaluation of antitumor and antitopoisomerase I activities.
    Lafayette EA; de Almeida SMV; Cavalcanti Santos RV; de Oliveira JF; Amorim CADC; da Silva RMF; Pitta MGDR; Pitta IDR; de Moura RO; de Carvalho Júnior LB; de Melo Rêgo MJB; de Lima MDCA
    Eur J Med Chem; 2017 Aug; 136():511-522. PubMed ID: 28531811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents.
    Dube PN; Sakle NS; Dhawale SA; More SA; Mokale SN
    Anticancer Agents Med Chem; 2019; 19(9):1150-1160. PubMed ID: 30848213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD).
    Dong J; Wang TL; Lu J; Ding CZ; Hu L; Hu G; He H; Zeng X; Li X; Sun D; Zhu Y; Shen L; Gu Q; Chan CC; Xia Y; Li J; Chen S
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127601. PubMed ID: 33035677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.